GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Accord BioPharma, Inc, the U.S. specialty division ofIntas Pharmaceuticals, Ltd.(&qu...
View DetailsGuangzhou, China --(BUSINESSWIRE)-- Bio-TheraSolutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, todayannounced that dosing has begun in Phase I clinical study to compare thepharmacokinetics and safety of BAT6005, a monoclonal an...
GUANGZHOU,China and MOSCOW, Russia ---(Businesswire)--- Bio-Thera Solutions, Ltd. (688177:SH), a commercial-stage biopharmaceuticalcompany developing a pipeline of innovative therapies and a pipeline ofbiosimilars, today announced the companyhas reac...
GUANGZHOU, China, September 27,2021 (BUSINESSWIRE) –Bio-Thera Solutions, Ltd. (688177.SH, “Bio-Thera”)and Intract Pharma (“Intract”) announced a global collaboration and licensingagreement that gives Bio-Thera access to Intract’s Soteria® and Phloral...
